Our Science

Pipeline

A new class of antifungal. Powerful. Different.

At SCYNEXIS, we believe that our innovative fungerp class of antifungals could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more. Learn more about our pipeline below.

SCY-247

Candida auris and other drug-resistant fungal infections*

*Partially supported by NIH grants

SCY-247
IND-enabling
IV & Oral

Ibrexafungerp

Invasive Candidiasis and Other Refractory Fungal Infections

SCY-247
Phase 3
Partner: GSK

Vulvovaginal Candidiasis (BREXAFEMME®)

SCY-247
Approved
Partner: GSK

GSK has an exclusive license for the development and commercialization of ibrexafungerp for all indications globally, except in the greater China region and certain other countries.

Our Science

Learn more about our commitment to protecting the world against dangerous and difficult-to-treat infectious diseases.

Learn More

Our data on invasive infections

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

Learn More